TABLE 2.
Historical and pre‐ITI data of study patients
| Data | Variable | All ITI population, n = 20 |
|---|---|---|
| Historical | Age at first exposure to FVIII, months | 5.5 (1–12) |
| FVIII treatment duration, months | 53 (24–139) | |
| Treatment, n (%) | ||
| Prophylaxis | 7 (35) | |
| On demand | 13 (65) | |
| Historical peak titre, BU | 41 (8–320) | |
| Pre‐ITI | Inhibitor titre at ITI start, BU | 36.5 (12–169) |
| Age at ITI start, years | 5 (3–12) | |
| Inhibitor diagnosis to start of ITI, months | 8.5 (.5–33) | |
| Type of FVIII at inhibitor detection | ||
| Plasma‐derived | 13 (65) | |
| Recombinant | 7 (35) | |
| FVIII recovery, % | 2 (1–4) |
Results are shown as number of patients and percentage or median (range), as applicable.
Abbreviations: ABR, annual bleeding rate; FVIII, Factor VIII; ITI, immune tolerance induction.